基于肿瘤原因的精子冷冻：一项回顾性研究

IF 3.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Reproductive biomedicine online Pub Date : 2025-01-01 DOI:10.1016/j.rbmo.2024.103898

Ana Santana-Plata , Rocio Rivera-Egea , Nicolás Garrido

{"title":"基于肿瘤原因的精子冷冻：一项回顾性研究","authors":"Ana Santana-Plata , Rocio Rivera-Egea , Nicolás Garrido","doi":"10.1016/j.rbmo.2024.103898","DOIUrl":null,"url":null,"abstract":"<div><h3>Research question</h3><div>How do cancer type and treatment affect semen quality before and after treatment, and what effect does it have in their clinical management of infertility? Also, what is the rate of patients using cryopreserved semen samples after treatment?</div></div><div><h3>Design</h3><div>Patients who cryopreserved spermatozoa for oncological reasons between 2000 and 2022 in IVI clinics in Spain were retrospectively reviewed. Semen parameters were analysed before and after treatment, and utilization and destruction rates were calculated. Total motile sperm count (TMSC) was used for assisted reproductive technology (ART) counselling.</div></div><div><h3>Results</h3><div>A total of 724 patients cryopreserved their semen during the study period. The semen parameters of the cancer patients' semen before and after treatment were heterogeneous, with significant differences between cancer type and semen parameters. The utilization rate was relatively low (0.4%), whereas the destruction rate was 23.1%.</div></div><div><h3>Conclusion</h3><div><span>Cancer and antineoplastic treatment affect everyone differently. Therefore, sperm </span>cryopreservation should be offered to all patients before starting treatment to ensure their reproductive future. Furthermore, in addition to considering the semen parameters defined by the World Health Organization, it is important to use TMSC in the diagnosis of men to choose appropriate ART according to type of cancer.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"50 1","pages":"Article 103898"},"PeriodicalIF":3.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Semen cryopreservation for an oncological reason: a retrospective study\",\"authors\":\"Ana Santana-Plata , Rocio Rivera-Egea , Nicolás Garrido\",\"doi\":\"10.1016/j.rbmo.2024.103898\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Research question</h3><div>How do cancer type and treatment affect semen quality before and after treatment, and what effect does it have in their clinical management of infertility? Also, what is the rate of patients using cryopreserved semen samples after treatment?</div></div><div><h3>Design</h3><div>Patients who cryopreserved spermatozoa for oncological reasons between 2000 and 2022 in IVI clinics in Spain were retrospectively reviewed. Semen parameters were analysed before and after treatment, and utilization and destruction rates were calculated. Total motile sperm count (TMSC) was used for assisted reproductive technology (ART) counselling.</div></div><div><h3>Results</h3><div>A total of 724 patients cryopreserved their semen during the study period. The semen parameters of the cancer patients' semen before and after treatment were heterogeneous, with significant differences between cancer type and semen parameters. The utilization rate was relatively low (0.4%), whereas the destruction rate was 23.1%.</div></div><div><h3>Conclusion</h3><div><span>Cancer and antineoplastic treatment affect everyone differently. Therefore, sperm </span>cryopreservation should be offered to all patients before starting treatment to ensure their reproductive future. Furthermore, in addition to considering the semen parameters defined by the World Health Organization, it is important to use TMSC in the diagnosis of men to choose appropriate ART according to type of cancer.</div></div>\",\"PeriodicalId\":21134,\"journal\":{\"name\":\"Reproductive biomedicine online\",\"volume\":\"50 1\",\"pages\":\"Article 103898\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reproductive biomedicine online\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1472648324000877\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive biomedicine online","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1472648324000877","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症类型和治疗方法对治疗前后的精液质量有何影响，对不育症的临床治疗有何影响？此外，患者在治疗后使用冷冻保存精液样本的比例是多少？我们对西班牙 IVI 诊所 2000 年至 2022 年间因肿瘤原因冷冻保存精子的患者进行了回顾性研究。对治疗前后的精液参数进行了分析，并计算了利用率和销毁率。总活力精子计数（TMSC）用于抗逆转录病毒疗法咨询。在研究期间，724 名患者对精液进行了冷冻保存。癌症患者在治疗前后的精液参数差异很大，癌症类型和精液参数之间存在显著差异。利用率相对较低（0.4%），而销毁率为 20%。癌症和抗肿瘤治疗对每个人的影响都不同。因此，在开始治疗前，所有患者都应进行精子冷冻保存，以确保他们的生殖前景。此外，除了考虑世卫组织规定的精液参数外，在诊断男性时还必须使用 TMSC，以便根据癌症类型选择合适的抗逆转录病毒疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Semen cryopreservation for an oncological reason: a retrospective study

Research question

How do cancer type and treatment affect semen quality before and after treatment, and what effect does it have in their clinical management of infertility? Also, what is the rate of patients using cryopreserved semen samples after treatment?

Design

Patients who cryopreserved spermatozoa for oncological reasons between 2000 and 2022 in IVI clinics in Spain were retrospectively reviewed. Semen parameters were analysed before and after treatment, and utilization and destruction rates were calculated. Total motile sperm count (TMSC) was used for assisted reproductive technology (ART) counselling.

Results

A total of 724 patients cryopreserved their semen during the study period. The semen parameters of the cancer patients' semen before and after treatment were heterogeneous, with significant differences between cancer type and semen parameters. The utilization rate was relatively low (0.4%), whereas the destruction rate was 23.1%.

Conclusion

Cancer and antineoplastic treatment affect everyone differently. Therefore, sperm cryopreservation should be offered to all patients before starting treatment to ensure their reproductive future. Furthermore, in addition to considering the semen parameters defined by the World Health Organization, it is important to use TMSC in the diagnosis of men to choose appropriate ART according to type of cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Reproductive biomedicine online 医学-妇产科学

CiteScore

7.20

自引率

7.50%

发文量

391

审稿时长

50 days

期刊介绍： Reproductive BioMedicine Online covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients. Context: The period of human embryonic growth covered is between the formation of the primordial germ cells in the fetus until mid-pregnancy. High quality research on lower animals is included if it helps to clarify the human situation. Studies progressing to birth and later are published if they have a direct bearing on events in the earlier stages of pregnancy.